LABRA

GOAL

Validation of the positive effects of photobiomodulation (PBM) therapy for the prevention of acute radiodermatitis in breast cancer patients 

STUDY DESIGN

Placebo-controlled, randomized trial with breast cancer patients undergoing radiotherapy after a breast sparing surgery at the Ziekenhuis Oost-Limburg and Jessa Hospital (NCT03924011)  from February 2019 until present

Control group (n=32)	PBM group (n=39)
Standard skin care	Standard skin care
Radiotherapy (hypofractionation regimen)	Radiotherapy (hypofractionation regimen)
Placebo treatment (2x/week, from start radiotherapy)	PBM (2x/week, from start radiotherapy)

STUDY RESULTS

At the final RT session 28% of the patients presented grade 2–3 ARD, while in the PBM group 10% presented grade 2 and no grade 3 ARD. PBM reduced the incidence of severe ARD by 18%. However, the difference was not significant (p = 0.053).

PUBLICATIONS

Robijns J, Lodewijckx J, Puts S, Vanmechelen S, Van Bever L, Claes S, Pannekoeke L, Timmermans A, Noé L, Govers M, Van de Werf E, Maes A, Bulens P, Mebis J. Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole-breast irradiation (LABRA trial). Lasers Surg Med. 2022 Mar;54(3):374-383. doi: 10.1002/lsm.23475. Epub 2021 Sep 4. PMID: 34481420.

PARTNERS